검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tildrakizumab |
Overview Company | Almirall, S.A. |
Overview Modality | ANTIBODY |
Overview Target | Psoriasis |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers of downstream IL23-IL23R activity, are now needed to translate IL23 blockade into the clinic |
PK/PD Half-life | 28 h |
PK/PD Species | Mouse, pharmacodynamics (PD), and antitumor activity. |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, pharmacodynamics (PD), and antitumor activity. |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.. Interleukin-23 (IL23) has been reported to drive androgen receptor (AR) and JAK2-STAT3 signaling, promoting treatment resistance and disease progression in advanced prostate cancer (PC). We evaluated the safety, tolerabi… |
Clinical Primary efficacy | ORR 85.07% |
Clinical ORR | 85.07% |
Clinical Result source | ClinicalTrials.gov NCT02980692 |
Clinical Data Tier / Score | A · 67 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tildrakizumab |
Overview Company | Almirall, S.A. |
Overview Modality | ANTIBODY |
Overview Target | Psoriasis |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers of downstream IL23-IL23R activity, are now needed to translate IL23 blockade into the clinic |
PK/PD Half-life | 28 h |
PK/PD Species | Mouse, pharmacodynamics (PD), and antitumor activity. |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, pharmacodynamics (PD), and antitumor activity. |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.. Interleukin-23 (IL23) has been reported to drive androgen receptor (AR) and JAK2-STAT3 signaling, promoting treatment resistance and disease progression in advanced prostate cancer (PC). We evaluated the safety, tolerabi… |
Clinical Primary efficacy | ORR 85.07% |
Clinical ORR | 85.07% |
Clinical Result source | ClinicalTrials.gov NCT02980692 |
Clinical Data Tier / Score | A · 67 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교